Cerebrolysin
Neuropeptides
ABOUT
Cerebrolysin is a preparation of low-molecular-weight peptides and amino acids. Randomised controlled studies have examined it in selected neurological conditions, including acute stroke and cognitive disorders.
EVIDENCE OVERVIEW
Early human findings, not yet confirmed
WHAT THIS MEANS
Potential. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Cerebrolysin is not a single molecule. It is a mixture of low-molecular-weight peptides and free amino acids derived from porcine brain, given intravenously, with proposed neuroprotective and neurotrophic properties. Because the composition is a biological extract rather than a defined chemical entity, no specific pharmacological mechanism has been established.
PHARMACOKINETICS
No pharmacokinetic data is available and the concept applies poorly to a heterogeneous mixture, since each constituent would have its own profile. Administered intravenously in doses referenced as 30-50 mL.
REVIEW
PUBLISHED PAIR RECORDS
with Semax
Overlapping neuroactive claims, none independently replicatedSemax and Cerebrolysin are commonly combined for cognitive or mood effects and are described as acting on overlapping neurotrophic and monoaminergic signalling rather than on separate targets. The shared problem is evidential rather than mechanistic: Semax is registered in Russia with an evidence base that is largely Russian-language and not independently replicated; Cerebrolysin is a porcine brain-derived peptide mixture whose Cochrane review found probably little or no benefit on all-cause death in acute ischaemic stroke, alongside moderate-quality evidence of a potential increase in non-fatal serious adverse events. No study has examined this combination, and for a pair where neither component has a replicated effect, a combined effect cannot be inferred from adding two uncertain ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with na-semax-amidate
Overlapping neuroactive claims, none independently replicatedNA Semax Amidate and Cerebrolysin are commonly combined for cognitive or mood effects and are described as acting on overlapping neurotrophic and monoaminergic signalling rather than on separate targets. The shared problem is evidential rather than mechanistic: NA Semax Amidate has no clinical trial of its own anywhere; Cerebrolysin is a porcine brain-derived peptide mixture whose Cochrane review found probably little or no benefit on all-cause death in acute ischaemic stroke, alongside moderate-quality evidence of a potential increase in non-fatal serious adverse events. No study has examined this combination, and for a pair where neither component has a replicated effect, a combined effect cannot be inferred from adding two uncertain ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Selank
Overlapping neuroactive claims, none independently replicatedSelank and Cerebrolysin are commonly combined for cognitive or mood effects and are described as acting on overlapping neurotrophic and monoaminergic signalling rather than on separate targets. The shared problem is evidential rather than mechanistic: Selank is registered in Russia, with one comparative anxiety report published in Russian; Cerebrolysin is a porcine brain-derived peptide mixture whose Cochrane review found probably little or no benefit on all-cause death in acute ischaemic stroke, alongside moderate-quality evidence of a potential increase in non-fatal serious adverse events. No study has examined this combination, and for a pair where neither component has a replicated effect, a combined effect cannot be inferred from adding two uncertain ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with na-selank-amidate
Overlapping neuroactive claims, none independently replicatedNA-Selank Amidate and Cerebrolysin are commonly combined for cognitive or mood effects and are described as acting on overlapping neurotrophic and monoaminergic signalling rather than on separate targets. The shared problem is evidential rather than mechanistic: NA-Selank Amidate has no clinical trial of its own anywhere; Cerebrolysin is a porcine brain-derived peptide mixture whose Cochrane review found probably little or no benefit on all-cause death in acute ischaemic stroke, alongside moderate-quality evidence of a potential increase in non-fatal serious adverse events. No study has examined this combination, and for a pair where neither component has a replicated effect, a combined effect cannot be inferred from adding two uncertain ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with noopept
Overlapping neuroactive claims, none independently replicatedNoopept and Cerebrolysin are commonly combined for cognitive or mood effects and are described as acting on overlapping neurotrophic and monoaminergic signalling rather than on separate targets. The shared problem is evidential rather than mechanistic: Noopept is prescribed in Russia and is an unapproved new drug in the United States, with a thin, largely developer-authored trial base; Cerebrolysin is a porcine brain-derived peptide mixture whose Cochrane review found probably little or no benefit on all-cause death in acute ischaemic stroke, alongside moderate-quality evidence of a potential increase in non-fatal serious adverse events. No study has examined this combination, and for a pair where neither component has a replicated effect, a combined effect cannot be inferred from adding two uncertain ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026HUMAN EVIDENCE
This is a case where more trials produced a clearer negative. A 2017 meta-analysis of 7 studies in 1,779 acute ischaemic stroke patients failed to demonstrate significant superiority on modified Rankin Scale or Barthel Index; a second 2017 meta-analysis of 6 RCTs in 1,649 patients found no significant effect on functional recovery at day 90. The 2020 Cochrane review of 7 RCTs in 1,601 participants concluded it probably has little or no beneficial effect on preventing all-cause death. Cochrane also flagged trial-quality problems: the manufacturer supported four of the multicentre studies, three carried high risk of other bias, and selective-reporting risk was unclear across all of them.
REPORTED EFFECTS
The safety signal is the more concerning finding. The 2016 Cochrane review concluded Cerebrolysin increased the risk of serious adverse events by at least one third; the 2020 update reported moderate-quality evidence of a potential increase in non-fatal serious adverse events. Mortality did not differ from placebo. A 2021 industry-adjacent analysis reported the opposite pattern on serious adverse events at high dose, which is part of why the evidence is characterised as conflicted rather than settled.
RESEARCH LIMITATIONS
Study results are indication-specific and mixed across outcomes and trials. This summary does not establish approval, safety for an individual, or a treatment recommendation.
CURATED SOURCES · 5